Evaluation of the meaningfulness of health‐related quality of life improvements as assessed by the SF‐36 and the EQ‐5D VAS in patients with active Crohn’s disease
Open Access
- 1 April 2009
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 29 (9), 1032-1041
- https://doi.org/10.1111/j.1365-2036.2009.03966.x
Abstract
Crohn's disease (CD) is a chronic inflammatory illness characterized by episodic abdominal pain, diarrhoea, fever, bleeding and obstruction. While the Crohn's Disease Activity Index (CDAI) remains the most commonly accepted measure for assessing the disease status in clinical trials, patient-reported outcome (PRO) instruments are being utilized more frequently to provide information about health-related quality of life (HRQOL). To facilitate interpretation of results, it is common to identify a meaningful unit of PRO score change, such as a minimal clinically important difference (MCID). To define and apply MCID estimates for the SF-36 and EuroQol-5D visual analogue scale (EQ-5D VAS) for use in CD treatment evaluation. Data from two phase III randomized controlled trials of certolizumab pegol were utilized. MCID estimates were computed from one trial using anchor-based and distribution-based methods. These estimates were applied to data from the other trial. SF-36 PCS and MCS MCID estimates ranged from 1.6 to 7.0 and 2.3 to 8.7 respectively, depending on approach. EQ-5D VAS MCID estimates ranged from 4.2 to 14.8. For the first time, the MCID values provided interpretation guidelines for PRO results in CD. This research demonstrates that patients treated with certolizumab pegol benefit from meaningful and sustained HRQOL improvements.Keywords
This publication has 18 references indexed in Scilit:
- Certolizumab Pegol for the Treatment of Crohn's DiseaseNew England Journal of Medicine, 2007
- Maintenance Therapy with Certolizumab Pegol for Crohn's DiseaseNew England Journal of Medicine, 2007
- Update on the incidence and prevalence of Crohnʼs disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000Inflammatory Bowel Diseases, 2007
- Responsiveness and minimal important differences for patient reported outcomesHealth and Quality of Life Outcomes, 2006
- Using Multiple Anchor- and Distribution-Based Estimates to Evaluate Clinically Meaningful Change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) InstrumentValue in Health, 2005
- Medical therapy for Crohn’s diseaseCurrent Opinion in Gastroenterology, 1999
- The Crohn’s Disease Activity Index, Its Derivatives and the Inflammatory Bowel Disease Questionnaire: A Review of Instruments to Assess in Crohn’s DiseaseCanadian Journal of Gastroenterology, 1999
- Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel diseaseGastroenterology, 1994
- Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study GroupEuropean Respiratory Journal, 1994
- Determining a minimal important change in a disease-specific quality of life questionnaireJournal of Clinical Epidemiology, 1994